Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
Nuvation Bio showcased longer-term Phase 2 data around the next-gen ROS1 inhibitor it hopes will give Pfizer and Bristol Myers Squibb a run for their money.
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
Nuvation Bio has accelerated its development into a commercial-stage biotech with a deal to acquire AnHeart Therapeutics and its late-stage lung cancer therapy taletrectinib.
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511